Guzik, T. J., and R. M. Touyz. 2017. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension 70:660–667.

Article  CAS  PubMed  Google Scholar 

Arevalo Martinez, M., O. Ritsvall, J. A. Bastrup, S. Celik, G. Jakobsson, F. Daoud, C. Winqvist, A. Aspberg, C. Rippe, L. Maegdefessel, A. Schiopu, T. A. Jepps, J. Holmberg, K. Sward, and S. Albinsson. 2023. Vascular smooth muscle-specific YAP/TAZ deletion triggers aneurysm development in mouse aorta. JCI Insight 8 (17): e170845.

Article  PubMed  PubMed Central  Google Scholar 

Qiu, Y., S. Xu, X. Chen, X. Wu, Z. Zhou, J. Zhang, Q. Tu, B. Dong, Z. Liu, J. He, X. Zhang, S. Liu, C. Su, H. Huang, W. Xia, and J. Tao. 2023. NAD(+) exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension. Signal Transduction and Targeted Therapy 8:353.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burnier, M., and A. Damianaki. 2023. Hypertension as cardiovascular risk factor in chronic kidney disease. Circulation Research 132:1050–1063.

Article  CAS  PubMed  Google Scholar 

Mancia, G., R. Kreutz, M. Brunstrom, M. Burnier, G. Grassi, A. Januszewicz, M.L. Muiesan, K. Tsioufis, E. Agabiti-Rosei, E. A. E. Algharably, M. Azizi, A. Benetos, C. Borghi, J. B. Hitij, R. Cifkova, A. Coca, V. Cornelissen, J. K. Cruickshank, P. G. Cunha, A. H. J. Danser, R. M. Pinho, C. Delles, A. F. Dominiczak, M. Dorobantu, M. Doumas, M. S. Fernandez-Alfonso, J. M. Halimi, Z. Jarai, B. Jelakovic, J. Jordan, T. Kuznetsova, S. Laurent, D. Lovic, E. Lurbe, F. Mahfoud, A. Manolis, M. Miglinas, K. Narkiewicz, T. Niiranen, P. Palatini, G. Parati, A. Pathak, A. Persu, J. Polonia, J. Redon, P. Sarafidis, R. Schmieder, B. Spronck, S. Stabouli, G. Stergiou, S. Taddei, C. Thomopoulos, M. Tomaszewski, P. Van de Borne, C. Wanner, T. Weber, B. Williams, Z. Y. Zhang, and S. E. Kjeldsen. 2023. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension 41:1874–2071.

Article  CAS  PubMed  Google Scholar 

McEvoy, J. W., C. P. McCarthy, R. M. Bruno, S. Brouwers, M. D. Canavan, C. Ceconi, R. M. Christodorescu, S. S. Daskalopoulou, C. J. Ferro, E. Gerdts, H. Hanssen, J. Harris, L. Lauder, R. J. McManus, G. J. Molloy, K. Rahimi, V. Regitz-Zagrosek, G. P. Rossi, E. C. Sandset, B. Scheenaerts, J. A. Staessen, I. Uchmanowicz, M. Volterrani, R. M. Touyz, Group, E. S. C. S. D. 2024. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal 45:3912–4018.

Article  PubMed  Google Scholar 

Ahwin, P., and D. Martinez. 2024. The relationship between SGLT2 and systemic blood pressure regulation. Hypertension Research 47 (8): 2094–2103.

Article  PubMed  PubMed Central  Google Scholar 

Sukhanov, S., Y. Higashi, T. Yoshida, S. Mummidi, A. R. Aroor, J. Jeffrey Russell, S. B. Bender, V. G. DeMarco, and B. Chandrasekar. 2021. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1beta and IL-18 secretion. Cellular Signalling 77:109825.

Article  CAS  PubMed  Google Scholar 

Nicolucci, A., R. Candido, D. Cucinotta, G. Graziano, A. Rocca, M. C. Rossi, F. Tuccinardi, and V. Manicardi. 2019. Generalizability of cardiovascular safety trials on SGLT2 inhibitors to the real world: Implications for clinical practice. Advances in Therapy 36:2895–2909.

Article  CAS  PubMed  Google Scholar 

Kario, K., K. C. Ferdinand, and J. H. O’Keefe. 2020. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Progress in Cardiovascular Diseases 63:249–262.

Article  PubMed  Google Scholar 

Zhang, Q., S. Zhou, and L. Liu. 2023. Efficacy and safety evaluation of SGLT2i on blood pressure control in patients with type 2 diabetes and hypertension: A new meta-analysis. Diabetology and Metabolic Syndrome 15:118.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanidas, E. A., D. P. Papadopoulos, E. Hatziagelaki, C. Grassos, M. Velliou, and J. Barbetseas. 2020. Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension. American Journal of Hypertension 33:207–213.

Article  CAS  PubMed  Google Scholar 

Scheen, A. J. 2019. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Current Cardiology Reports 21:70.

Article  PubMed  Google Scholar 

Sternlicht, H., and G. L. Bakris. 2019. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): More than osmotic diuresis. Current Hypertension Reports 21:12.

Article  PubMed  Google Scholar 

Chiriaco, M., D. Trico, and A. Solini. 2022. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors. Current Opinion in Pharmacology 66:102272.

Article  CAS  PubMed  Google Scholar 

Hu, M., X. Cai, W. Yang, S. Zhang, L. Nie, and L. Ji. 2020. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: A meta-analysis. Journal of the American Heart Association 9:e015323.

Article  PubMed  PubMed Central  Google Scholar 

Kharitonenkov, A., and R. DiMarchi. 2017. Fibroblast growth factor 21 night watch: Advances and uncertainties in the field. Journal of Internal Medicine 281:233–246.

Article  CAS  PubMed  Google Scholar 

Flippo, K. H., and M. J. Potthoff. 2021. Metabolic messengers: FGF21. Nature Metabolism 3:309–317.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Geng, L., K. S. L. Lam, and A. Xu. 2020. The therapeutic potential of FGF21 in metabolic diseases: From bench to clinic. Nature Reviews. Endocrinology 16:654–667.

Article  CAS  PubMed  Google Scholar 

Jin, L., L. Geng, L. Ying, L. Shu, K. Ye, R. Yang, Y. Liu, Y. Wang, Y. Cai, X. Jiang, Q. Wang, X. Yan, B. Liao, J. Liu, F. Duan, G. Sweeney, C. W. H. Woo, Y. Wang, Z. Xia, Q. Lian, and A. Xu. 2022. FGF21-Sirtuin 3 axis confers the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity. Circulation 146:1537–1557.

Article  CAS  PubMed  Google Scholar 

Heng, Y., W. Wei, L. Cheng, F. Wu, H. Dong, J. Li, J. Fu, B. Yang, X. Liang, C. Liu, H. Li, H. Liu, and P. Zhang. 2024. FGF21 overexpression alleviates VSMC senescence in diabetic mice by modulating the SYK-NLRP3 inflammasome-PPARgamma-catalase pathway. Acta Biochimica et Biophysica Sinica (Shanghai) 56:892–904.

CAS  Google Scholar 

Osataphan, S., C. Macchi, G. Singhal, J. Chimene-Weiss, V. Sales, C. Kozuka, J. M. Dreyfuss, H. Pan, Y. Tangcharoenpaisan, J. Morningstar, R. Gerszten, and M. E. Patti. 2019. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI Insight 4 (5): e123130.

Article  PubMed  PubMed Central  Google Scholar 

Packer, M. 2020. Cardioprotective effects of Sirtuin-1 and its downstream effectors: Potential role in mediating the heart failure benefits of SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors. Circulation Heart Failure 13:e007197.

Article  CAS  PubMed  Google Scholar 

Pan, X., Y. Shao, F. Wu, Y. Wang, R. Xiong, J. Zheng, H. Tian, B. Wang, Y. Wang, Y. Zhang, Z. Han, A. Qu, H. Xu, A. Lu, T. Yang, X. Li, A. Xu, J. Du, and Z. Lin. 2018. FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/Angiotensin-(1–7) axis in mice. Cell Metabolism 27:1323-1337 e5.

Article  CAS  PubMed  Google Scholar 

Norgaard, S. A., F. Briand, F. W. Sand, E. D. Galsgaard, H. Sondergaard, D. B. Sorensen, and T. Sulpice. 2019. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin. European Journal of Pharmacology 860:172537.

Article  PubMed  Google Scholar 

Wang, L., X. C. Zhao, W. Cui, Y. Q. Ma, H. L. Ren, X. Zhou, J. Fassett, Y. Z. Yang, Y. Chen, Y.L. Xia, J. Du, and H. H. Li. 2016. Genetic and pharmacologic inhibition of the chemokine receptor CXCR2 prevents experimental hypertension and vascular dysfunction. Circulation 134:1353–1368.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Marco, E., S. P. Gray, K. Kennedy, C. Szyndralewiez, A. N. Lyle, B. Lassegue, K. K. Griendling, M. E. Cooper, H. Schmidt, and K. A. M. Jandeleit-Dahm. 2016. NOX4-derived reactive oxygen species limit fibrosis and inhibit proliferation of vascular smooth muscle cells in diabetic atherosclerosis. Free Radical Biology & Medicine 97:556–567.

Article  Google Scholar 

Che, H., Y. Wang, H. Li, Y. Li, A. Sahil, J. Lv, Y. Liu, Z. Yang, R. Dong, H. Xue, and L. Wang. 2020. Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-beta1/Smads signaling in diabetic cardiomyopathy. The FASEB Journal 34:5282–5298.

Article  CAS  PubMed